Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2010

01-04-2010 | Case Report

Severe ifosfamide-induced neurotoxicity: a case report

Authors: Sara Ramos Linares, Joaquín Breña Atienza, Matilde Cháfer Rudilla, Pablo Ríos Rull, Ana Cabello Rodríguez, Javier Merino Alonso

Published in: International Journal of Clinical Pharmacy | Issue 2/2010

Login to get access

Abstract

Introduction Ifosfamide is an alkylating agent used in the treatment of several neoplasias. Ifosfamide metabolites accumulation can produce neurotoxicity, which sometimes manifests as a severe clinical picture. Case description We describe the case of a male with a mixed cellularity subtype classical Hodgkin’s lymphoma, treated with ifosfamide after other chemotherapy drugs failure. After the first Ifosfamide cycle, the patient showed severe neurological toxicity that resolved 3 weeks later with supportive therapy. Discussion Among the risk factors described in the literature, our patient had previously received cysplatin chemotherapy, had low albumin serum levels, and had received ifosfamide as a rapid intravenous infusion. The management of the neurotoxicity is symptomatic although some drugs, like methylene blue and albumin, have also been used. Conclusion This case highlights that clinicians should be aware of the possibility of severe neurological toxicity after the administration of ifosfamide and may control the risk factors associated.
Literature
1.
go back to reference Klatersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2):7–10.CrossRef Klatersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2):7–10.CrossRef
2.
go back to reference Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 2004;15:347–50.CrossRefPubMed Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 2004;15:347–50.CrossRefPubMed
3.
go back to reference Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol. 2007;19(2):108–14.CrossRef Ajithkumar T, Parkinson C, Shamshad F, Murray P. Ifosfamide encephalopathy. Clin Oncol. 2007;19(2):108–14.CrossRef
4.
go back to reference Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, vinorelbine: a new induction regimen for refractory, relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41.CrossRefPubMed Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, vinorelbine: a new induction regimen for refractory, relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41.CrossRefPubMed
7.
go back to reference Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006;40:299–303.CrossRefPubMed Patel PN. Methylene blue for management of ifosfamide-induced encephalopathy. Ann Pharmacother. 2006;40:299–303.CrossRefPubMed
8.
go back to reference David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28(3):277–80.CrossRefPubMed David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28(3):277–80.CrossRefPubMed
9.
go back to reference Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006;2(40):299–303. Hamadani M, Awan F. Role of thiamine in managing ifosfamide-induced encephalopathy. J Oncol Pharm Pract. 2006;2(40):299–303.
10.
go back to reference Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291–4.CrossRefPubMed Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291–4.CrossRefPubMed
Metadata
Title
Severe ifosfamide-induced neurotoxicity: a case report
Authors
Sara Ramos Linares
Joaquín Breña Atienza
Matilde Cháfer Rudilla
Pablo Ríos Rull
Ana Cabello Rodríguez
Javier Merino Alonso
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-009-9354-4

Other articles of this Issue 2/2010

International Journal of Clinical Pharmacy 2/2010 Go to the issue